LXEO Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Advances DoubleVerify Q1 2026 Earnings EPS Misses Estimates Stock Declines Milestone Pharmaceuticals MIST Q1 2026 Earnings EPS Miss Deepens as ClinicalStage Biotech Navigates Development Path Nathans Famous Inc NATH Q4 2024 Earnings EPS of 096 Reported as Stock Moves Lower VEEE Q2 2025 Earnings Narrower Loss Propels Stock Higher Amid Strategic Transition HYPR Q1 2026 Earnings EPS Beat Highlights Cost Discipline Amid Disclosed Revenue Gap